EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Aclaris Therapeutics, Inc (0H8T) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Aclaris Therapeutics, Inc $0.95, price $4.34, upside -78.1%, quality 30 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

GB · ISIN US00461U1051

AT Thin data Sep 24, 2026

Aclaris Therapeutics, Inc

0H8T · LSE

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.9500 · Strongly overvalued (−78.1%)
!Quality 30/100
!Weak Growth (revenue 5y +3.8 %/yr)
!negative free cash flow
!Narrow moat 8/100
!Evidence only low, so the estimate is less certain

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$6.58 $2.60 Fair Value $0.9500 Dec 2025 Oct 2026

White line = price, green steps = our fair value per fiscal year. As of Sep 24, 2026.

How to read this chart

10‑month range $2.60 – $6.58 · fair‑value band $0.6300 – $1.19 · the $4.34 price screens above the $0.9500 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States.

Show more

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Stock analysis

Aclaris Therapeutics, Inc (0H8T) currently trades at $4.34, while our model-based Fair Value estimate is $0.9500, 78.1% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $0.6300 (bear) to $1.19 (bull), the price of $4.34 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality).

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Aclaris Therapeutics, Inc reported revenue of $7.8M in FY2025 versus $6.8M in FY2021, a compound +3.7%/yr. Reported net income was −$64.9M in FY2025.

Key figures

Market cap $532M · EPS (TTM) $−1.36 · Return on equity −48.4% · Return on assets (EBIT) −35.3% · Operating margin −1,112% · Revenue (TTM) $8.4M · Revenue growth (YoY) +37.2% · Free cash flow −$47.2M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

Fair Value models

Bear $0.6300 Fair Value $0.9500 Bull $1.19
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $1.26 $1.69 $2.52 51
All 1 models by family
Asset-Based
NCAV (Graham) $1.26 $1.69 $2.52 51

Open the full fair value analysis →

Notify me when 0H8T reaches fair value

Put 0H8T on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 30/100

Of which business quality 32 · Market factors (momentum, volatility) 49

Profitability 0
Margins and returns on capital today
Quality Growth 26
Are margins and returns improving?
Cashflow 5
Earnings quality: real cash, not paper profit
Fin. Strength 80
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 40
Calm price path (market factor)
Momentum 42
Price trend over the last 3–12 months (market factor)
52W Momentum 72
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 14/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−58.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−35.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.8%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−748.5% (2020) → −944.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 0H8T, get fair value alerts →

Compare Aclaris Therapeutics, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Aclaris Therapeutics, Inc · Fair Value
$0.9500 −78%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Aclaris Therapeutics, Inc Fair Value". https://www.fairvalue-calculator.com/stock/0H8T

Frequently asked questions

Is Aclaris Therapeutics, Inc (0H8T) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.9500 versus a price of $4.34, about −78% upside (overvalued).
What is the fair value of 0H8T?
Our model-based fair value for Aclaris Therapeutics, Inc is $0.9500 (as of Sep 24, 2026), built from audited fundamentals. The current price: $4.34.
What is the quality score of 0H8T?
Aclaris Therapeutics, Inc has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Aclaris Therapeutics, Inc (0H8T)?
Our model-based price target is the fair value of $0.9500 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $0.6300, optimistic scenario $1.19. It is a calculation from audited fundamentals, not an analyst target.
What is the Aclaris Therapeutics, Inc stock forecast for 2026?
Our models put fair value at $0.9500, about −78% upside versus a price of $4.34 (overvalued). Cautious scenario $0.6300, optimistic scenario $1.19. The calculation is refreshed regularly with new filings.
What is the revenue of Aclaris Therapeutics, Inc (0H8T)?
Aclaris Therapeutics, Inc reported trailing-twelve-month revenue of about $8.4M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Aclaris Therapeutics, Inc (0H8T)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Aclaris Therapeutics, Inc it is $0.9500 per share (as of Sep 24, 2026), against a price of $4.34. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Aclaris Therapeutics, Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0H8T trades above its calculated fair value: price $4.34, fair value $0.9500, a gap of about −78% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0H8T?
No. The price is what the market pays today ($4.34); the fair value is what the company's own numbers justify ($0.9500). For Aclaris Therapeutics, Inc the two are $3.39 per share apart. That gap is exactly why we show both numbers side by side.
How much is Aclaris Therapeutics, Inc worth?
The market values Aclaris Therapeutics, Inc at about $532M (market capitalisation, as of Sep 24, 2026). Per share that is $4.34; our models calculate a fair value of $0.9500 per share.
What do the bullish and bearish scenarios say about 0H8T?
Our models span a range for Aclaris Therapeutics, Inc: cautious scenario $0.6300, base $0.9500, optimistic $1.19 per share (as of Sep 24, 2026, price $4.34). The range comes from different growth and margin assumptions, not from analyst opinions.
Is Aclaris Therapeutics, Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $4.34, calculated fair value $0.9500 (−78%), Quality Score 30/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0H8T calculated?
We run Aclaris Therapeutics, Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.9500, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Aclaris Therapeutics, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Aclaris Therapeutics, Inc (0H8T)?
The closing price on Oct 2, 2026 was $4.34. Our model-based fair value is $0.9500, about −78% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Aclaris Therapeutics, Inc right now?
The price sits above even our optimistic bull case ($1.19). The favourable scenario is already priced in. Weak quality (30/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.6300 to $1.19) leaves room in how you read the outcome.

Key figures of Aclaris Therapeutics, Inc

How large is the market capitalisation of Aclaris Therapeutics, Inc (0H8T)?
The market capitalisation of Aclaris Therapeutics, Inc is $532M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Aclaris Therapeutics, Inc (0H8T)?
Earnings per share at Aclaris Therapeutics, Inc are $−1.36. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Aclaris Therapeutics, Inc (0H8T)?
The return on equity (ROE) of Aclaris Therapeutics, Inc is −48.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Aclaris Therapeutics, Inc (0H8T)?
On an EBIT basis the return on assets of Aclaris Therapeutics, Inc is −35.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Aclaris Therapeutics, Inc (0H8T)?
The operating margin of Aclaris Therapeutics, Inc is −1,112% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Aclaris Therapeutics, Inc (0H8T)?
Revenue at Aclaris Therapeutics, Inc is growing +37.2% versus a year earlier (3y avg −35.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Aclaris Therapeutics, Inc (0H8T) generate?
The free cash flow of Aclaris Therapeutics, Inc is −$47.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Aclaris Therapeutics, Inc (0H8T) hold?
Aclaris Therapeutics, Inc holds more cash than debt, $16.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Continue in the live analysis

Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.